How The Harvard Bioscience (HBIO) Investment Narrative Is Resetting After Lower 2026 Expectations

The latest update on Harvard Bioscience centers on a sharp reset in expectations, with the fair value estimate cut from US$2.00 to US$0.60. Analysts are using this lower target to reflect the revised ...

Harvard Bioscience Announces Reverse Stock Split

Detailed price information for Harvard Bioscience (HBIO-Q) from The Globe and Mail including charting and trades.

Harvard Bioscience outlines 2026 guidance with 2%–4% revenue growth and high-margin focus following structural improvements

Q4 2025 earnings call recap: revenue, margins, refinancing, cost cuts, and 2026 guidance on growth and EBITDA—read now.

Harvard Bioscience Approves Reverse Stock Split to Regain Compliance

Detailed price information for Harvard Bioscience (HBIO-Q) from The Globe and Mail including charting and trades.
WBJournal

Harvard Bioscience Inc.

Harvard Bioscience, a life science equipment manufacturer based in Holliston, reported a net loss of $410,000 for the company’s second quarter financials in an earnings report released on Thursday.

Harvard Bioscience (HBIO) Earnings Transcript

Full-year Revenue -- $86.6 million, an 8% decline primarily attributable to tariffs and delayed NIH funding. Full-year Adjusted EBITDA -- $8.1 million, up 12.5% year over year, attributed to cost ...
Seeking Alpha

Harvard Bioscience targets $22.5M–$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution

The company is guiding to a revenue range of $22.5 million to $24.5 million for Q4 2025, with Frost noting, "The lower end of the range reflects the potential risk of a prolonged U.S. government ...
MarketWatch

Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States

The MarketWatch News Department was not involved in the creation of this content. HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or ...
Insider Monkey

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2025 Earnings Call Transcript

Harvard Bioscience has a strong operating team, a culture committed to advancing science and an innovation pipeline that positions us well for long-term growth. Since joining the company, I’ve ...
Business Insider

Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum

HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief ...

Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost ...
WBJournal

Harvard Bioscience Inc.

Jim Green will retire from his roles as chairman, president, and CEO of Harvard Bioscience on July 28. Harvard Bioscience falls out of Nasdaq compliance after board member resignation Harvard ...